If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

PSA Screening Reduces Prostate Cancer Mortality, European Study Shows

May 24, 2012

The European Randomized Study of Screening for Prostate Cancer (ERSPC), which included 186,160 men, suggests that PSA screening can lower prostate cancer mortality rates.
 

Cure Possible Despite Positive Lymph Nodes

May 21, 2012

Long-term PSA relapse-free survival after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is possible in a subset of patients with low volume nodal metastases, a researcher reported at the American Urological Association 2012 annual meeting.
 

Prostate Cancer Screening: Moving Beyond PSA

May 01, 2012

More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.
 

After Radical Prostatectomy, Patient Learns He Never Had Prostate Cancer

May 01, 2012

Dr. B, 57, was a urologist with a busy private practice. One of his patients was Mr. O, 69, who had an abnormal PSA result.
 

Should percent free PSA be used in the decision to perform initial prostate biopsy in men with moderately elevated PSA?

April 06, 2012

A recently published paper reported on the development of an improved nomogram for predicting outcomes of initial biopsies based on readily available clinical information.
 

PSA Screening Lowers Prostate Cancer Mortality

March 16, 2012

PSA-based screening significantly decreases the risk of dying from prostate cancer (PCa), according to updated results of a large European study.
 

Survey: Leading Urologists Favor Routine PSA Tests

October 31, 2011

Most leading urologists recommend routine PSA testing for men aged 50 and older, despite a recent U.S. panel's recommendation, according to a survey by U.S. News World & Report.
 

Urologists Oppose U.S. Panel's Stance Against PSA Testing

October 12, 2011

Urologists have voiced opposition to a national panel's recommendation that healthy men should not undergo PSA screening.
 

Prostate Cancer Drug May Delay Time to Second-Line Treatment

September 29, 2011

Degarelix may delay time to second-line therapy and improve PSA control and in men with advanced hormone-dependent prostate cancer, according to long-term data from an extension study. John Schieszer has the story in today's Medical Minute.
 

PSA Testing: Why the U.S. and Europe Differ

September 21, 2011

Solid evidence for a survival benefit from PSA screening for prostate cancer is lacking, but the practice is more widespread in the United States than in many European countries.
 

Factors May Identify Prostate Cancer Patients Most Likely to Benefit from Salvage Therapy

August 19, 2011

Patients with lower pre-salvage radical prostatectomy PSA levels and a lower post-radiation prostate biopsy Gleason score may have the highest probability for cure with salvage radical prostatectomy. John Schieszer explains in today's Medical Minute.
 

Earlier PSA Screening May Make Annual Testings Unnecessary

June 06, 2011

CHICAGO—PSA levels at the time of initial screening among men aged 44-50 years can accurately predict the risk that a man will die from prostate cancer (PCa) or develop metastatic PCa up to 30 years later, a Swedish study found.
 

MRI Scans May Improve PCa Recurrence at Low PSA Levels

May 03, 2011

Dynamic contrast enhanced (DCE) endorectal magnetic resonance imaging (MRI) of the pelvis may offer an effective method of assessing for local recurrence of prostate cancer (PCa) after prostatectomy, according to Texas researchers.
 

Flaws of PSA Screening Include Unnecessary Testing of Older Men

April 20, 2011

Prostate-specfic antigen (PSA)-based prostate cancer screening in the U.S. appears to have some serious flaws. It appears that many elderly men may be undergoing unnecessary PSA testing.
 

High PSA Velocity Alone Is Not Enough Reason for Biopsy

March 29, 2011

An analysis of 5,519 men undergoing biopsy in the control arm of the Prostate Cancer Prevention Trial uncovered no evidence to support the recommendation that men with high PSA velocity be biopsied in the absence of other indications, according to an online report in the Journal of the National Cancer Institute.
 

PSA Screening Lowers Metastasis Risk

March 19, 2011

VIENNA—PSA screening for prostate cancer (PCa) decreases the risk of PCa-related metastatic disease, according to study findings presented at the European Association of Urology 26th annual congress.
 

Pomegranate Extract May Slow Prostate Cancer Advance

February 18, 2011

ORLANDO—A pomegranate extract slowed progression of prostate cancer (PCa) in a study of men who had rising PSA levels after primary treatment for the malignancy.
 

Dutasteride May Lead to More Reliable PSA Screening

January 12, 2011

The PSA screening test for prostate cancer is far from perfect. However, a new study suggests the test may be more reliable in men taking dutasteride (Avodart®). John Schieszer explains in today's Medical Minute.
 

PSA Levels in Men Age 55-60

November 15, 2010

New data are suggesting that a baseline PSA level of 1 ng/mL at age 55 or 60 may mean men need no further screening. These finding may further tailor how the PSA test is used. John Schieszer has the latest in today's Medical Minute.
 

Obese Men Have Lower PSA-Driven Biopsy Rates

October 07, 2010

Syndicated medical journalist John Schieszer reports on new research showing that, among men who undergo PSA tests, those who are obese are significantly less likely to have a PSA level of 4 ng/mL or higher, a widely used criterion for undergoing a prostate biopsy.
 

PSA at Age 60 Predicts Prostate Cancer Death Risk

October 01, 2010

PSA levels measured at age 60 predict a man's lifetime risk of metastasis and death from prostate cancer (PCa), according to a study published online in the British Medical Journal.
 

Baseline PSA Predicts Prostate Cancer Death Risk

September 24, 2010

Baseline PSA levels reliably and independently predicts death from prostate cancer, with a baseline reading of 4 ng/mL or higher linked with greater mortality risk.
 

Initial PSA Value After Salvage Cryoablation Predictive

September 24, 2010

Initial PSA levels following salvage cryoabation in prostate cancer patients who failed radiation therapy may predict the likelihood of long-term biochemical progression, researchers found.
 

PSA Testing Found to Reduce Prostate Cancer Mortality

August 19, 2010

Deaths from prostate cancer (PCa) fell by almost half after 14 years of biennial screening, according to data from a Swedish study.
 

PSA Rises More Slowly with Age in Diabetics

June 03, 2010

SAN FRANCISCO—Men with diabetes experience significantly smaller increases in PSA level as they age compared with non-diabetics, according to findings reported here at the American Urological Association Annual Meeting.
 

PSA Lower in Aspirin-Using Never Smokers

April 01, 2010

Aspirin use is associated with lower PSA levels in men who have never smoked, data suggest.
 

PCA3 Beats PSA in Predicting Prostate Biopsy Outcomes

March 05, 2010

SAN FRANCISCO—The prostate cancer gene 3 (PCA3) molecular urine test is more accurate than the PSA test in predicting outcomes of repeat biopsies, new findings confirm.
 

PSA Levels Decline After The Start of Statin Therapy

January 15, 2010

Onset of statin use is associated with a significant reduction in serum PSA level, data suggest.
 

PSA Testing Rate Highest in Blacks

December 15, 2009

A study of a large multiethnic cohort found that African-American men had a higher prevalence of PSA screening than white and Latino men.
 

Undetectable PSA Possible With Radiation

December 10, 2009

After a median of 32 months, PSA was undetectable in 12% of patients.
 

BMI Affects PSA Test Results in Whites

September 18, 2009

The likelihood of an abnormal finding is 46% lower in obese men than normal-weight men, study shows
 

PSM Site Predicts PSA Relapse Risk

September 17, 2009

Positive margins at the prostate base are associated with the worst outcomes.
 

Adenovirus/PSA Vaccine Shows Promise

September 17, 2009

Researchers observe positive T cell responses in men with nonmetastatic recurrence prostate cancer.
 

PSADT Predicts Mortality

July 22, 2009

Among men who experience PSA recurrence following radical prostatectomy (RP) for prostate cancer, a PSA doubling time (PSADT) of less than nine months at the time of recurrence is associated with a significantly increased risk of death, according to a study.
 

PSAs of 1.5-4 Hike PCa Risk

July 13, 2009

ORLANDO—Men with PSA values of 1.5-4 ng/mL have a significantly elevated four-year risk of being diagnosed with prostate cancer compared with men who have PSA levels below 1.5, according to a retrospective study of 21,502 men.
 

Statins May Prevent PSA Relapse

June 30, 2009

Prostate cancer patients who use statins may be at lower risk of PSA recurrence after radical prostatectomy (RP) compared with those who do not use the medications, according to investigators.
 

Study Defines PCa Metastasis Predictors

June 18, 2009

PSA doubling time (PSADT), Gleason score, and time to PSA progression are strong independent predictors of metastasis-free survival in prostate cancer patients who experience PSA recurrence following radical prostatectomy (RP).
 

Soy Well-Tolerated in PCa Patients

June 18, 2009

DENVER—Consuming 20 g of soy daily for up to two years is safe and may be beneficial for men at high risk for biochemical failure after radical prostatectomy, according to preliminary findings from an ongoing study.
 

Delayed PSA Recurrence a Good Sign

June 16, 2009

PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with better cancer-specific survival than PSAR less than five years after surgery, a study found.
 

Pomegranate Juice May Help Prostate Cancer Patients

May 28, 2009

Pomegranate juice may help slow progression of prostate cancer in men who experience rising PSA levels following radical prostatectomy or radiotherapy, data suggest.
 

PSA Screening Cuts Prostate Cancer Death Risk

May 01, 2009

PSA screening for prostate cancer is associated with a 20% reduction in mortality from the disease, according to findings from the largest prostate cancer study ever conducted.
 

PSA Density Predicts Worse Prostate Cancer Pathology

April 29, 2009

PSA density (PSAD) predicts pathologic upstaging following radical prostatectomy (RP) for prostate cancer, a study found.
 

New AUA Recommendation: Start Offering PSA Testing at 40

April 27, 2009

CHICAGO—The American Urological Association (AUA) recommends that PSA testing should be offered to well-informed men aged 40 years and older who have a life expectancy of at least 10 years.
 

PSA Is Not Enough to Assess Prostate Cancer Risk

April 17, 2009

Canadian researchers say it may be time to move beyond PSA-based predictions of prostate cancer risk. New technology and gene-based markers make it possible to use a more individualized approach that considers all prostate cancer risk factors.
 

Prostate Cancer Possible Even if PSA Declines

March 23, 2009

Men whose PSA levels rise above 4 ng/mL—a commonly used threshold for prostate biopsy—but then decline to below this level can still harbor prostate cancer, and many of these cancers may be aggressive.
 

Prebiopsy Antibiotics May Be Unjustified

March 16, 2009

New findings raise questions about the practice of prescribing antibiotics to men prior to prostate biopsy if they have newly elevated PSA levels and a normal digital rectal examination (DRE).
 

After the PSA Cutoff Era: The Importance of Context

March 01, 2009

About two years ago, having recognized that the prostate-specific antigen (PSA) cutoff level of 4.0 ng/mL did not always assist in accurately categorizing a man's risk for prostate cancer, we began to eliminate this—or any—artificial cutoff defining a "normal" PSA value.
 

Study: Salvage Prostatectomy Is Effective

January 30, 2009

Salvage radical prostatectomy (SP) is an effective treatment for prostate cancer patients who experience local failure following radiotherapy, according to researchers.
 

Urine Assay for Prostate Cancer Advances

January 23, 2009

SAN DIEGO—A commercial assay may prove to be valuable for determining which men with elevated prostate-specific antigen (PSA) levels or an abnormal digital rectal exam (DRE) are likely to have prostate cancer and hence should undergo biopsy.
 

Popular Drugs Found to Decrease PSA Levels

December 08, 2008

Two of the most common classes of medication — statins and nonsteroidal anti-inflammatory drugs (NSAIDs) — may compromise cancer screenings by lowering serum prostate-specific antigen (PSA) levels, according to two studies.
 

A Clinical Dilemma: What is Normal?

December 08, 2008

The concept of what is "normal" enters into nearly every aspect of clinical decision making. For physicians to declare something abnormal and make a diagnosis, they must first know what normal is.
 

ADT-Related Anxiety Linked to Elevated PSA

November 14, 2008

Men with elevated serum PSA levels prior to beginning androgen deprivation therapy (ADT) for prostate cancer are nearly eight times more likely to experience anxiety after starting ADT, researchers reported.
 

Radiation Aids PCa Survival

November 01, 2008

BOSTON—Men with locally advanced prostate cancer can reduce their risk of dying from the malignancy by adding radiation treatment to anti-androgen therapy, according to a study that researchers believe to be the first of its kind.
 

A New Way to Stratify High-Risk PCa Patients

November 01, 2008

BOSTON—Prostate cancer patients with a Gleason score of 9 or 10 have a risk of PSA recurrence following radical prostatectomy or radiation therapy similar to that of men having a Gleason score of 7 with tertiary grade 5 disease, data suggest.
 

Study: NSAIDs May Lower PSA Levels

September 09, 2008

Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen may decrease serum levels of PSA, which could affect detection of prostate cancer, according to a report in Cancer (2008; published online ahead of print).
 

PCA3 Urine Test Superior

September 02, 2008

The prostate cancer gene 3 (PCA3) urine test is superior to percent-free PSA in predicting prostate biopsy outcome, data show.
 

PCa Screening Not Advised at Age 75+

September 01, 2008

Updating its 2002 recommendations, a federal government panel now advises against screening for prostate cancer in men aged 75 years and older.
 

Prostate Cancer Patient Sues Over Late Diagnosis

August 28, 2008

For more than 30 years, most of the patients in Dr. R's thriving primary care practice had been of retirement age. Now that he was 62, they were his contemporaries. Dr. R treated patients the way that he wanted to be treated— with respect and without unnecessary tests.
 

Baseline PSA Value Can Predict PCa Up to 30 Years Later

August 25, 2008

ORLANDO—Premalignant phases of prostate cancer occur over long periods of time and a single PSA measurement taken at age 44-50 can help predict prostate cancer diagnosis up to 30 years subsequently, according to updated findings from a study of Swedish men.
 

PSA Tests Can Be Stopped In Some Men

July 21, 2008

ORLANDO—Men who have PSA levels below 3 ng/mL at age 75-80 years may be able to safely discon-tinue regular prostate cancer screenings, according to researchers.
 

Study Challenges Safety of Close Margins

July 15, 2008

DENVER—Close surgical margins in radical prostatectomy specimens could place patients at increased risk of PSA failure, according to a study that may challenge conventional wisdom.
 

PCa At End of Biopsy Core A Bad Sign

July 15, 2008

DENVER—The presence of tumor cells at the end of a needle biopsy core obtained near the capsule is an independent indicator of a significantly elevated risk of extracapsular extension, according to data presented here at the annual meeting of the United States and Canada Academy of Pathology.
 

PSA Is Lower in Diabetics

July 15, 2008

Serum PSA levels are lower in men with type 2 diabetes than in healthy men, researchers reported in Diabetes Care (2008;31:930-931).
 

Sextant Biopsy Alone May Miss Tumors

May 06, 2008

Prostate biopsies in men with a PSA level of 4.01-10.0 ng/mL and normal findings on digital rectal examination (DRE) should include lateral cores in addition to the sextant biopsy, according to investigators.
 

Lower PSAV Threshold Useful

May 06, 2008

SAN FRANCISCO—A PSA velocity (PSAV) threshold of 0.4 ng/mL per year can distinguish between clinically significant and insignificant prostate cancer, new data suggest.
 

Repeat PSA Tests May Aid Prostate Biopsy Decisions

May 06, 2008

Following an initial PSA test result of 3.0-19.99 ng/mL in men aged 50-70 years, a repeat PSA test within seven weeks allows for more accurate assessment as to whether a biopsy will reveal prostate cancer, a British team reports.
 

Antibiotics May Fail To Lower PSA

May 05, 2008

Long-term antibiotic therapy for men with biopsy-proven asymptomatic prostatitis may not significantly alter elevated PSA levels, data show.
 

Elevated PSA Often Meets with Delayed Response

May 01, 2008

Delayed clinician response to a patient's abnormal PSA level occurs in about 23% of cases, which may be more common than is generally appreciated, according to researchers.
 

PSA Density More Predictive

May 01, 2008

PSA density is strongly associated with pathological stage and biochemical-free survival after radical prostatectomy for prostate cancer, researchers conclude.
 

PSA Testing Varies by Race

May 01, 2008

Black men may be getting the message that they are at increased risk of prostate cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention (2008;17:636-644).
 

TRUS Alone is Not Enough for Prostate Cancer Detection

April 11, 2008

Gray-scale transrectal ultrasonography (TRUS) alone has a limited potential to detect prostate cancer, particularly in patients with total PSA levels below 20 ng/mL, researchers reported in the Journal of Medical Imaging and Radiation Oncology (2008;52:24-28).
 

Antibody Assay Could Aid in Assessing Prostate Disease

January 01, 2008

Using an assay they developed to detect antibodies to Propionibacterium acnes bacteria, researchers have found a link between these bacteria and development of inflammation-related prostate diseases.
 

Hemodilution Lowers PSA Levels

January 01, 2008

Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers.
 

Lower PSA Linked to Greater Plasma Volume in Obese PCa Patients

November 20, 2007

Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers.
 

PSA Density Predicts PSA Velocity, UK Study Shows

November 01, 2007

PSA density is an independent determinant of PSA velocity in untreated localized prostate cancer, a study in the UK concluded.
 

Novel Agent May Benefit Men with Metastatic HRPC

September 10, 2007

CHICAGO—A new compound that specifically inhibits production of the cell-survival protein clusterin appears to be well tolerated and produces PSA responses when given in combination with docetaxel and prednisone in men with metastatic hormone refractory prostate cancer (HRPC), a study found.
 

New PCa Test More Accurate Than PSA

August 03, 2007

An experimental blood test has detected prostate cancer so accurately that it could supplant PSA levels as a screening mechanism for the disease, according to researchers.
 

Testosterone Considered Safe for Older Men

August 01, 2007

TORONTO—Six months of testosterone supplementation in older men with moderately low testosterone levels appears to be relatively safe, with little or no negative effects on the prostate, according to researchers in The Netherlands.
 

PCPs May Miss LUTS Cases

August 01, 2007

ANAHEIM, Calif.—Moderate to severe lower urinary tract symptoms (LUTS) are present in 42% of men over age 50 who visit their primary-care physician (PCP), according to data presented here at the American Urological Association annual meeting.
 

PCa Death Decline Tied To Screening

August 01, 2007

ANAHEIM, Calif.—Declines in prostate cancer deaths are associated with an increase in PSA screening, although the effect is greater in white than in black men, according to researchers at the University of Alabama-Birmingham.
 

Watchful Waiting Risks Quantified

July 01, 2007

ANAHEIM, Calif.—Fifteen percent of older men managed with watchful waiting for low-risk prostate tumors detected by PSA screening will die from the malignancy in 10 years, despite a high death rate from competing causes, a study found.
 

Statins Found to Decrease PSA Levels

July 01, 2007

ANAHEIM, Calif.—Statins can significantly reduce PSA levels in healthy men, and the magnitude of this decline is proportional to the extent to which the drugs reduce cholesterol levels, according to researchers.
 

Screening-Detected PCa May Be Less Risky

July 01, 2007

ANAHEIM, Calif.—Prostate cancers found as a result of PSA screening are less likely to exhibit extracapsular extension and positive surgical margins after radical prostatectomy than tumors found in a non-screened population, despite similar PSA levels, data show.
 

Active Surveillance in PCa: When Is it the Right Choice?

June 01, 2007

For some men with localized prostate cancer, active surveillance has emerged in recent years as a viable management option.
 

Avoid Prostate Biopsies In Octogenarians?

May 16, 2007

Prostate biopsies may be unwarranted in men aged 80 years and older and who have a PSA level of 30 ng/mL, according to investigators in the U.K.
 

PCa Risk Not Lower in Men with Fluctuating PSA Level

May 08, 2007

Contrary to what is commonly thought, the risk of having a positive repeat prostate biopsy is no lower for men with a fluctuating PSA level than it is for those with a steady or steadily increasing PSA level.
 

What Constitutes Locally Advanced PCa?

April 25, 2007

The most widespread nondermatologic malignancy in men, prostate cancer afflicts one in six American males and kills one in 34. Growing public awareness, an aging population, and increased PSA screening has led to greater detection of early-stage disease.
 

Urine Test May Improve PCa Diagnosis

April 25, 2007

ORLANDO—A urine assay for prostate cancer gene 3 (PCA3) is superior to serum PSA tests for predicting outcomes of repeat prostate biopsy, data show.
 

PSA Velocity Threshold is Too High

April 25, 2007

ORLANDO—New findings presented here suggest clinicians should use a lower PSA velocity (PSAV) to recommend prostate biopsies in men who have PSA levels less than 4 ng/mL.
 

Neoadjuvant PCa Therapy: An Update

April 24, 2007

In the PSA era, most men with newly diagnosed prostate cancer present with clinically localized disease and are curable with surgery or radiation.
 

IMRT Shows Promise for PCa Salvage

April 24, 2007

ORLANDO—Intensity-modulated radiation therapy (IMRT) may offer a promising salvage option for prostate cancer patients who experience PSA relapse following radical prostatectomy, researchers said.
 

Screening Cuts Risk of Advanced PCa

March 01, 2007

Biennial PSA screening decreases the likelihood of being diagnosed with metastatic prostate cancer, but nearly doubles the chance of being diagnosed with prostate cancer of any type, a Swedish sudy found.
 

PSA Velocity A Better Predictor

March 01, 2007

Preoperative PSA velocity is more useful than PSA doubling time for predicting outcomes after radical prostatectomy for prostate cancer, according to researchers.
 

Lower PSA Biopsy Threshold Advised

March 01, 2007

Diagnostic PSA levels in men younger than 50 years are significantly lower than guidelines suggest, according to researchers.
 

Drug for Baldness Affects PSA Testing

March 01, 2007

As little as 1 mg/day of finasteride can seriously distort the results of a PSA screening for prostate cancer, a recent study has found.
 

Lower PSA Biopsy Cutoff Supported

December 01, 2006

African-American (AA) men with nonpalpable prostate cancer have greater cancer volumes and higher prostatectomy Gleason scores than white men with similar PSA levels at the time of biopsy, according to a study.
 

Higher PSA Hikes Rescue Failure Risk

December 01, 2006

PSA levels and PSA doubling time (PSADT) prior to radiotherapy predict outcomes following rescue radiation therapy for men with prostate cancer.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Kidney Cancer Overactive Bladder Prostate Cancer PSA Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions